Results 71 to 80 of about 423,899 (348)

Quantification of Pulmonary Arterial Wall Distensibility Using Parameters Extracted from Volumetric Micro-CT Images [PDF]

, 1999
Stiffening, or loss of distensibility, of arterial vessel walls is among the manifestations of a number of vascular diseases including pulmonary arterial hypertension.
Dawson, Christopher A, Johnson, Roger H., Karau, Kelly Lynn, Molthen, Robert C.   +3 more
core   +2 more sources

The arterial load in pulmonary hypertension [PDF]

European Respiratory Review, 2010
The anatomical differences between the pulmonary and systemic arterial system are the main cause of the difference in distribution of compliance. In the pulmonary arterial system compliance is distributed over the entire arterial system, and stands at the basis of the constancy of the RC-time.
Saouti, N., Westerhof, N., Postmus, P.E., Vonk Noordegraaf, A.   +3 more
openaire   +4 more sources

Management of Pulmonary Arterial Hypertension [PDF]

Current Cardiovascular Risk Reports, 2020
This review focuses on the therapeutic management and individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food and Drug Administration-approved PAH-specific therapies and various interventional and surgical options for PAH.The paradigm for the optimal management of PAH has shifted in recent years.
Emily Beck, Tara L. Jones, Irene Z. Pan, Jennalyn D. Mayeux, John J. Ryan, Joshua A. Jacobs, John Dechand, Nathan D. Hatton, Stephen H. McKellar   +8 more
openaire   +2 more sources

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

Molecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho, Yubin Hah, Eunsik Yun, Hye In Ka, Aram Lee, Sora Han, Dawn Lee, Sung Wook Kim, Jong Hoon Park, Byung Su Kwon, Young Yang, Jongmin Kim   +11 more
wiley   +1 more source

Pulmonary hypertension associated with neurofibromatosis type 2

Pulmonary Circulation, 2021
Although precapillary pulmonary hypertension is a rare but severe complication of patients with neurofibromatosis type 1 (NF1), its association with NF2 remains unknown.
Hirohisa Taniguchi, Tomoya Takashima, Ly Tu, Raphaël Thuillet, Asuka Furukawa, Yoshiko Furukawa, Akio Kawamura, Marc Humbert, Christophe Guignabert, Yuichi Tamura   +9 more
doaj   +1 more source

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

European Respiratory Journal, 2017
Current European guidelines recommend periodic risk assessment for patients with pulmonary arterial hypertension (PAH). The aim of our study was to determine the association between the number of low-risk criteria achieved within 1 year of diagnosis and ...
A. Boucly, J. Weatherald, L. Savale, X. Jaïs, V. Cottin, G. Prévôt, F. Picard, P. De Groote, M. Jevnikar, E. Bergot, A. Chaouat, C. Chabanne, A. Bourdin, F. Parent, D. Montani, G. Simonneau, M. Humbert, O. Sitbon   +17 more
semanticscholar   +1 more source

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. [PDF]

, 2018
Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension ...
Ayon, Ramon J, Balistrieri, Angela, Black, Stephen M, Chen, Jiwang, Desai, Ankit A, Garcia, Joe GN, Gu, Yali, Makino, Ayako, Rischard, Franz, Song, Shanshan, Tang, Haiyang, Vanderpool, Rebecca, Vinjamuri, Sujana, Wang, Jian, Wang, Ziyi, Wu, Kang, Yuan, Jason X-J, Zhang, Qian, Zhou, Guofei   +18 more
core   +1 more source

Pulmonary arterial hypertension: an update [PDF]

Netherlands Heart Journal, 2011
Pulmonary arterial hypertension (PAH), defined as group 1 of the World Heart Organisation (WHO) classification of pulmonary hypertension, is an uncommon disorder of the pulmonary vascular system. It is characterised by an increased pulmonary artery pressure, increased pulmonary vascular resistance and specific histological changes.
openaire   +4 more sources

SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher, Dominika Stastna, Ingrid Menkyova, Vaclav Capek, Jiri Lindner, Petra Nytrova, Jan Krasensky, Eliza Varju, Miguel D'haeseleer, Eva Kubala Havrdova, Dana Horakova, Manuela Vaneckova, Niels Bergsland   +12 more
wiley   +1 more source

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model

European Respiratory Journal, 2017
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH).
M. Hoeper, T. Kramer, Z. Pan, C. Eichstaedt, J. Spiesshoefer, N. Benjamin, K. Olsson, K. Meyer, C. Vizza, A. Vonk-Noordegraaf, O. Distler, C. Opitz, J. Gibbs, M. Delcroix, H. Ghofrani, D. Huscher, D. Pittrow, S. Rosenkranz, E. Grünig   +18 more
semanticscholar   +1 more source